| Indicators | Browse All

Palatin Technologies, Inc. (PTN)

Healthcare | Biotechnology | Monmouth Junction, United States | NasdaqCM
9.52 USD -0.48 (-4.800%) ⇩ (July 13, 2026, 4 p.m. EDT)
After hours: 9.60 +0.08 (0.840%) ⇧ (July 13, 2026, 4:10 p.m. EDT)

Short-term:★☆☆☆☆Long-term:⯪☆☆☆☆Dividends:☆☆☆☆☆
Hot Take | July 11, 2026, 5:30 a.m. EDT

The immediate outlook is severely clouded by a massive 99% collapse in share price over the last decade, driven by four consecutive years of negative annual returns. While the company recently executed a capital raise and moved to the Nasdaq, the underlying business is hemorrhaging cash with negative free cash flow, negative operating margins, and a forward P/E that indicates expected losses. The statistical forecast model, which is designed to catch short-term noise, also leans slightly negative, reinforcing the bearish sentiment rather than offering a contrarian bounce. With no dividend to provide income and a balance sheet showing significant cash burn relative to its tiny market cap, there is no compelling case for a near-term recovery or a long-term hold.

Model Selection — Backtest MAE (log-scale, lower is better)
ModelMAE
AutoTheta ✓0.381872
MSTL0.383131
AutoARIMA0.390389
AutoETS0.392773

Forecast horizon: 45 days | Selected: AutoTheta

Forecast Reliability
Score 34%
H-stat 8.28
Ljung-Box p 0.000
Jarque-Bera p 0.421
Excess Kurtosis -0.81
Attribute Value
Sector Healthcare
Debt to Equity Ratio 2.706
Revenue per Share 6.277
Market Cap 16,938,698
Trailing P/E 95.20
Forward P/E -3.92
Beta -0.07
Profit Margins -48.50%
Website https://palatin.com

Info Dump

Attribute Value
52 Week Change 0.53846157
Address1 11 Deer Park Drive
Address2 Suite 204
All Time High 128,125.0
All Time Low 2.0
Ask 10.5
Ask Size 1
Average Daily Volume10 Day 32,110
Average Daily Volume3 Month 17,332
Average Volume 17,332
Average Volume10Days 32,110
Beta -0.07
Bid 0.0
Bid Size 200
Book Value 5.963
City Monmouth Junction
Compensation As Of Epoch Date 1,767,139,200
Country United States
Crypto Tradeable 0
Currency USD
Current Price 9.52
Current Ratio 5.041
Custom Price Alert Confidence HIGH
Date Short Interest 1,782,777,600
Day High 10.04
Day Low 9.5
Debt To Equity 2.706
Display Name Palatin
Ebitda -8,752,423
Ebitda Margins -0.67931
Enterprise To Ebitda -0.807
Enterprise To Revenue 0.548
Enterprise Value 7,065,940
Eps Current Year -2.99
Eps Forward -2.43
Eps Trailing Twelve Months 0.1
Esg Populated 0
Exchange NCM
Exchange Data Delayed By 0
Exchange Timezone Name America/New_York
Exchange Timezone Short Name EDT
Fifty Day Average 14.249
Fifty Day Average Change -4.728999
Fifty Day Average Change Percent -0.3318829
Fifty Two Week Change Percent 53.846157
Fifty Two Week High 31.0
Fifty Two Week High Change -21.48
Fifty Two Week High Change Percent -0.6929032
Fifty Two Week Low 5.0
Fifty Two Week Low Change 4.5200005
Fifty Two Week Low Change Percent 0.9040001
Fifty Two Week Range 5.0 - 31.0
Financial Currency USD
First Trade Date Milliseconds 876,922,200,000
Float Shares 1,384,205
Forward Eps -2.43
Forward P E -3.9176955
Free Cashflow -13,673,166
Full Exchange Name NasdaqCM
Full Time Employees 29
Gmt Off Set Milliseconds -14,400,000
Gross Margins 0.0428
Gross Profits 551,402
Has Pre Post Market Data 1
Held Percent Insiders 0.07888
Held Percent Institutions 0.55578
Implied Shares Outstanding 1,779,275
Industry Biotechnology
Industry Disp Biotechnology
Industry Key biotechnology
Ipo Expected Date 2,026-05-29
Language en-US
Last Fiscal Year End 1,751,241,600
Last Split Date 1,754,956,800
Last Split Factor 1:50
Long Business Summary Palatin Technologies, Inc., a biopharmaceutical company, develops first-in-class medicines based on molecules that modulate the activity of the melanocortin receptor system in the United States. It is developing oral small molecule PL7737 MC4R agonist in preclinical studies; long-acting peptide MC4R agonists; and Bremelanotide co-administration with Tirzepatide to treat obesity in Phase 2 trial, as well as Bremelanotide co-formulated with a PDE5i for the treatment of ED in patients not adequately responsive to PDE5i monotherapy. The company also develops PL9643 for dry eye disease and anti-inflammatory ocular indications; and oral PL8177 for the treatment inflammatory bowel diseases. Palatin Technologies, Inc. was incorporated in 1986 and is based in Monmouth Junction, New Jersey.
Long Name Palatin Technologies, Inc.
Market us_market
Market Cap 16,938,698
Market State PREPRE
Max Age 86,400
Message Board Id finmb_32651
Most Recent Quarter 1,774,915,200
Net Income To Common -6,249,112
Next Fiscal Year End 1,782,777,600
Non Diluted Market Cap 17,774,957
Number Of Analyst Opinions 3
Open 9.8801
Operating Cashflow -14,932,332
Operating Margins -0.40325
Payout Ratio 0.0
Peg Ratio 1.62
Phone 609 495 2200
Post Market Change 0.07999992
Post Market Change Percent 0.8403353
Post Market Price 9.6
Post Market Time 1,783,973,404
Previous Close 10.0
Price Eps Current Year -3.1839466
Price Hint 2
Price To Book 1.596512
Price To Sales Trailing12 Months 1.3146814
Profit Margins -0.48501998
Quick Ratio 4.861
Quote Source Name Nasdaq Real Time Price
Quote Type EQUITY
Recommendation Key none
Region US
Regular Market Change -0.47999954
Regular Market Change Percent -4.7999954
Regular Market Day High 10.04
Regular Market Day Low 9.5
Regular Market Day Range 9.5 - 10.04
Regular Market Open 9.8801
Regular Market Previous Close 10.0
Regular Market Price 9.52
Regular Market Time 1,783,972,800
Regular Market Volume 8,496
Return On Assets -0.65259004
Return On Equity -2.9723902
Revenue Per Share 6.277
Sand P52 Week Change 0.20847368
Sector Healthcare
Sector Disp Healthcare
Sector Key healthcare
Shares Outstanding 1,779,275
Shares Percent Shares Out 0.1026
Shares Short 182,616
Shares Short Previous Month Date 1,780,012,800
Shares Short Prior Month 183,059
Short Name Palatin Technologies, Inc.
Short Percent Of Float 0.1079
Short Ratio 12.58
Source Interval 15
State NJ
Symbol PTN
Target High Price 60.0
Target Low Price 47.5
Target Mean Price 53.5
Target Median Price 53.0
Total Cash 10,159,494
Total Cash Per Share 5.71
Total Debt 286,662
Total Revenue 12,884,261
Tradeable 0
Trailing Annual Dividend Rate 0.0
Trailing Annual Dividend Yield 0.0
Trailing Eps 0.1
Trailing P E 95.200005
Trailing Peg Ratio None
Triggerable 1
Two Hundred Day Average 15.75175
Two Hundred Day Average Change -6.2317495
Two Hundred Day Average Change Percent -0.39562267
Type Disp Equity
Volume 8,496
Website https://palatin.com
Zip 8,512